Company attributes
Other attributes
Neurelis was founded by Craig Charles Chambliss and David F. Hale in 2007 by investing about US$4 million.
Neurelis is focused on the development and commercialization of product candidates for epilepsy and the broader central nervous system (CNS) market. On 10 January 2020, the US Food and Drug Administration (FDA) approved Neurelis' VALTOCO, a diazepam nasal spray.
Neurelis has acquired Aegis Therapeutics, a drug delivery technology company based in San Diego, in 2018. This acquisition helps Neurelis to include Aeagis’ Intravail which is designed to increase spray absorption with less variability, in their core product Valtoco. Through this purchase, Neurelis gains licensing deals with Dr. Reddy's Laboratories and Opiant Pharmaceuticals.
The company's core product is called Valtoco, a formulation that incorporates diazepam, an existing drug used to control seizures and alcohol withdrawal, with a vitamin E-based solution that is delivered using a nasal spray when a sudden seizure episode occurs. The product uses an absorption enhancement technology called Intravail, developed by Aegis Therapeutics. Valtoco is indicated for the treatment of intermittent, stereotypic episodes of frequent seizure activities (seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in the adult and pediatric patients 6 years of age and older.
